Lineage Cell Therapeutics
LCTX
107 hedge funds and large institutions have $113M invested in Lineage Cell Therapeutics in 2018 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 33 increasing their positions, 21 reducing their positions, and 17 closing their positions.
57% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 21
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1.15% less ownership
Funds ownership: 44.5% → 43.35% (-1.1%)
7% less funds holding
Funds holding: 115 → 107 (-8)
34% less call options, than puts
Call options by funds: $109K | Put options by funds: $164K
47% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 17
53% less capital inflows, than outflows
Capital inflows: $3.49M | Capital outflows: $7.35M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$1.33M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$556K |
| 3 |
State Street
Boston,
Massachusetts
|
+$417K |
| 4 |
Two Sigma Investments
New York
|
+$147K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$124K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$1.45M |
| 2 |
Destination Wealth Management
Walnut Creek,
California
|
-$1.42M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1M |
| 4 |
MHP
Manatuck Hill Partners
Westport,
Connecticut
|
-$747K |
| 5 |
Laurion Capital Management
New York
|
-$472K |
LCTX Hedge Fund Activity: Q2 2018 in Review
107 of the 4,386 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q2 2018, worth a combined $113M — down 25% from $152M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of LCTX and 9 opened new positions — a net loss of 8 holders — while 21 trimmed existing stakes and 33 added.
The largest buyer was BlackRock, adding an estimated $1.33M. The largest seller was Renaissance Technologies, cutting an estimated $1.45M.
- 107 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q2 2018, down from 115 in Q1 2018.
- Funds reported $113M of Lineage Cell Therapeutics stock for Q2 2018, down 25% quarter-over-quarter.
- 9 funds opened new Lineage Cell Therapeutics positions in Q2 2018 and 17 closed out, a net change of -8 holders.
- The largest Lineage Cell Therapeutics buyer in Q2 2018 was BlackRock, an estimated $1.33M added.
- The largest Lineage Cell Therapeutics seller in Q2 2018 was Renaissance Technologies, an estimated $1.45M sold.
Based on aggregated 13F filings for Q2 2018.